SCHEMBL5791006

SCHEMBL5791006

CC(C)N1CCC[C@H](Cn2c(C(F)F)nc3ccc(Br)cc3c2=O)C1

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.67
GHSR Q92847 11/20 0.58
KCNH2 Q12809 8/20 0.58
CYP3A4 P08684 1/20 0.55
CACNA2D1 P54289 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5791009 0.93 CYP2D6 (0.74) CYP2D6GHSRKCNH2CYP3A4CACNA2D1
SCHEMBL5791730 0.88 GHSR (0.73) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5791737 0.87 CYP2D6 (0.58) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5795087 0.87 CYP2D6 (0.58) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5791115 0.86 GHSR (0.58) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5790809 0.86 GHSR (0.58) CYP2D6GHSRKCNH2CYP3A4CACNA2D1
SCHEMBL5794554 0.86 CYP2D6 (0.90) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5820677 0.84 GHSR (0.59) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5791441 0.84 GHSR (0.76) CYP2D6GHSRKCNH2CYP3A4
SCHEMBL5794299 0.81 CYP2D6 (0.57) CYP2D6GHSRKCNH2CYP3A4CACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1673084-A1 1-2' (1,4'-BIPERIDIN-1'-YL)-1-(PHENYL)-ETHYLCYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS Wyeth (US) 2006-06-28 EP disclosed
WO-2006012577-A2 QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE BAYER PHARMACEUTICALS CORPORATION (US) 2006-02-02 WO disclosed
WO-2005037279-A1 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS WYETH (US) 2005-04-28 WO disclosed